Voglis Stefanos, Quinn Kieran, Tullis Elizabeth, Liu Mingyao, Henriques Melanie, Zubrinich Celia, Peñuelas Oscar, Chan Holman, Silverman Frances, Cherepanov Vera, Orzech Neil, Khine Aye Aye, Cantin André, Slutsky Arthur S, Downey Gregory P, Zhang Haibo
The Keenan Research Centre, Li Ka Shing Knowledge Institute of St. Michael's Hospital, Toronto, Ontario, Canada.
Am J Respir Crit Care Med. 2009 Jul 15;180(2):159-66. doi: 10.1164/rccm.200808-1250OC. Epub 2009 Apr 30.
A well-known clinical paradox is that severe bacterial infections persist in the lungs of patients with cystic fibrosis (CF) despite the abundance of polymorphonuclear neutrophils (PMN) and the presence of a high concentration of human neutrophil peptides (HNP), both of which are expected to kill the bacteria but fail to do so. The mechanisms remain unknown.
This study examined several possible mechanisms to understand this paradox.
PMN were isolated from sputum and blood of subjects with and without CF or non-CF bronchiectasis for phagocytic assays. HNP isolated from patients with CF were used to stimulate healthy PMN followed by phagocytic tests.
PMN isolated from the sputum of the bronchiectatic patients display defective phagocytosis that correlated with high concentrations of HNP in the lung. When healthy PMN were incubated with HNP, decreased phagocytic capacity was observed in association with depressed surface Fc gamma RIII, actin-filament remodeling, enhanced intracellular Ca(2+), and degranulation. Treatment of PMN with an intracellular Ca(2+) blocker or alpha1-proteinase inhibitor to attenuate the activity of HNP largely prevented the HNP-induced phagocytic deficiency. Intratracheal instillation of HNP in Pallid mice (genetically deficient in alpha1-proteinase inhibitor) resulted in a greater PMN lung infiltration and phagocytic deficiency compared with wild-type mice.
HNP or PMN alone exert antimicrobial ability, which was lost as a result of their interaction. These effects of HNP may help explain the clinical paradox seen in patients with inflammatory lung diseases, suggesting HNP as a novel target for clinical therapy.
一个广为人知的临床悖论是,尽管囊性纤维化(CF)患者肺部有大量多形核中性粒细胞(PMN)且存在高浓度的人中性粒细胞肽(HNP),但严重细菌感染仍持续存在,而这两者都预期能杀死细菌却未能做到。其机制仍不明。
本研究探讨了几种可能机制以理解这一悖论。
从有或无CF或非CF支气管扩张症的受试者痰液和血液中分离PMN进行吞噬试验。从CF患者中分离的HNP用于刺激健康PMN,随后进行吞噬测试。
从支气管扩张症患者痰液中分离的PMN表现出吞噬功能缺陷,这与肺中高浓度的HNP相关。当健康PMN与HNP一起孵育时,观察到吞噬能力下降,同时伴有表面FcγRIII降低、肌动蛋白丝重塑、细胞内Ca(2+)增强和脱颗粒。用细胞内Ca(2+)阻滞剂或α1-蛋白酶抑制剂处理PMN以减弱HNP的活性,很大程度上预防了HNP诱导的吞噬缺陷。与野生型小鼠相比,向苍白小鼠(α1-蛋白酶抑制剂基因缺陷)气管内滴注HNP导致更大程度的PMN肺浸润和吞噬缺陷。
单独的HNP或PMN具有抗菌能力,但它们相互作用后这种能力丧失。HNP的这些作用可能有助于解释炎症性肺病患者中出现的临床悖论,提示HNP作为临床治疗的新靶点。